黑料不打烊

Global Downstream Processing Market Trends and Insights

Rapid Expansion of Global Biologics Manufacturing Capacity

Samsung Biologics completed its fifth plant in April 2025, lifting global capacity to 784,000 L and reinforcing a volume race that lifts demand for large-scale chromatography systems and single-use bioreactors.^{[1]Eli Lilly, 鈥淟illy Announces New USD 4.5 Billion Site to Drive Innovation in Drug Production,鈥� investor.lilly.com} Newly built lines favor continuous modalities that lower buffer consumption by as much as 40% and reduce water-for-injection requirements. Regional governments position biomanufacturing as a strategic growth engine, illustrated by Saudi Arabia鈥檚 plan to add USD 34.6 billion to non-oil GDP by 2040.^{[2]Vision 2030, 鈥淣ational Biotechnology Strategy,鈥� vision2030.gov.sa} In November 2024, Lonza completed a USD 1.2 billion acquisition of Roche's 330,000-liter Vacaville site, enhancing its capacity with protein-A chromatography and viral-filtration capabilities while avoiding the extended lead time required for new facility construction. In March 2025, Lotte Biologics committed USD 1 billion to establish a 250,000-liter facility in Songdo, focusing on biosimilar purification at cost levels suitable for emerging markets. In January 2025, Novartis announced a USD 23 billion manufacturing program in the United States, with a significant portion allocated to downstream automation and integrated skids aimed at reducing labor requirements per batch.

Rising R&D Spending Among Big Pharma & Emerging Biotech

In 2025, pharmaceutical R&D investments reached USD 294 billion, with biologics accounting for 62%.^{[3]U.S. Food and Drug Administration, 鈥淐DER and CBER Biologics Approvals,鈥� U.S. Food and Drug Administration, fda.gov} This shift toward large molecules and the restructuring of small-molecule portfolios due to patent cliffs is significant. The FDA approved 14 new biologics in 2025, with each launch requiring substantial drug-substance volumes.^{[4]Nature Editorial Team, 鈥淐ontinuous Bioprocessing,鈥� Nature Biotechnology, nature.com} These volumes translate into frequent purification campaigns, driving consistent demand for chromatography resins and viral filters. Higher approval rates validate new capacities and strengthen budget allocations for downstream automation, which reduces per-gram costs and enhances accessibility for mid-tier indications. As development portfolios increasingly focus on antibodies, ADCs, and bispecifics, the complexity of downstream purification has grown. This has led to a rising demand for orthogonal chromatography media and validated single-use assemblies. These trends support sustained order flows for integrated equipment-consumable ecosystems within the downstream processing market.

CMO/CDMO Outsourcing Boom with Multi-Year Capacity Deals

Survey data show CDMOs could operate 54% of global biologics capacity by 2028, altering purchasing cycles for buffers, probes, and membrane adsorbers. Multi-year reserved-capacity contracts de-risk capital for smaller sponsors and accelerate technology transfer. In 2024, Celltrion launched a CDMO division and successfully obtained contracts for the purification of biosimilars adalimumab and trastuzumab, leveraging South Korea's cost-efficient labor market. Fujifilm Diosynth invested USD 850 million in a gene-therapy facility in North Carolina, equipping it with continuous-chromatography trains and acoustic-wave separation technology to optimize AAV purification cycles. Innovators are converting fixed manufacturing costs into variable fees by utilizing CDMO expertise in validation, electronic records compliance, and change control, thereby reducing regulatory risks during product launches. CDMOs are distributing the costs of high-value skids and resins across multiple clients, improving utilization rates, enhancing cost predictability for sponsors, and ensuring reliable capacity in the downstream processing market.

Continuous Bioprocessing Adoption Lowering CAPEX/OPEX

Continuous downstream trains have transformed the biopharmaceutical manufacturing process by consolidating steps such as clarifying, capturing, viral inactivation, polishing, and ultrafiltration into a single integrated system. This approach enables 24/7 operations, significantly reduces facility footprints, and accelerates time-to-market. In February 2024, the FDA issued draft guidance supporting continuous manufacturing for biologics, provided that sponsors demonstrate real-time PAT monitoring and implement robust control strategies to ensure quality. In 2025, Eli Lilly introduced a continuous three-column protein-A system at its Indianapolis facility, achieving improved resin utilization and reduced buffer consumption, which delivered measurable annual cost savings. Sartorius launched a continuous platform that integrates perfusion bioreactors with inline chromatography, targeting lower production costs at the 500-kilogram scale. While adoption remains concentrated among large pharmaceutical companies and leading CDMOs due to the upfront investment and expertise required in multivariate process control, this shift establishes a cost benchmark that could expand the range of biologic indications over time.

High Capital Cost of Chromatography Skids & Resins

In the biotechnology sector, financial investments are substantial. A fully automated continuous-chromatography skid, integrated with inline viral inactivation and buffer-management modules, is priced at USD 4鈥�6 million. This significant cost creates financial challenges for academic spin-outs and early-stage biotech companies. Protein-A resins, critical in bioprocessing, are priced between USD 12,000 and 18,000 per liter. A large monoclonal antibody (mAb) campaign often requires hundreds of liters for both capture and polishing stages, leading to multi-million-dollar consumable expenses, excluding additional costs such as filters and buffers. In price-sensitive markets, downstream capital and consumables frequently account for the majority of bioprocessing cost-of-goods, limiting access for emerging biosimilar developers. To mitigate these costs, vendors are extending resin lifetimes. Newer protein-A media, for instance, offer cycle counts that significantly exceed those of first-generation products, although replacement costs remain a considerable expense over the product lifecycle.

Purification Bottleneck Versus Upstream Titers

By 2026, upstream titers for monoclonal antibodies are expected to exceed 10 grams per liter. However, many downstream processes remain designed for lower-output regimes. This misalignment creates increased volume pressure, longer production cycles, and capacity constraints. These challenges contribute to protein-A column fouling and necessitate mid-cycle regeneration, leading to higher idle times, greater cleaning solution consumption, and slower manufacturing throughput. High-titer eluates can also clog viral filters, doubling membrane area requirements and driving up per-campaign costs, particularly at commercial scales. The production of bispecifics and antibody-drug conjugates introduces additional steps, such as ion-exchange and hydrophobic-interaction chromatography, which extend purification times and occupy suites that could otherwise support additional campaigns. Continuous processing offers a potential solution by maintaining steady-state loading and eliminating batch equilibration. However, the need for full re-validation under regulatory guidance adds time and effort, delaying immediate capacity improvements.

*Our updated forecasts treat driver/restraint impacts as directional, not additive. The revised impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Technique: Purification Dominates, Disruption Accelerates

Purification techniques accounted for 32.05% of the downstream processing market revenue in 2025, confirming their centrality to biologics quality. Cell disruption registers the fastest 14.88% CAGR as microbial and intracellular expression systems gain adoption. The downstream processing market size for purification surpassed USD 14.75 billion in 2026 and is poised to cross USD 27 billion by 2031, supported by resin capacity expansions and multicolumn innovations. In parallel, homogenisers and microfluidisers remain the workhorses for cell disruption, but low-frequency acoustic methods are attracting pilot-scale trials because they generate less heat. 

Continuous chromatography reduces buffer use, aligning with sustainability objectives that influence procurement in Europe. Single-use centrifuges and depth-filtration cassettes improve clarification throughput and minimise contamination risk, a feature valued in multi-product CDMO suites. Integration software that harmonises sensor readings across clarification and capture stages shortens batch release times, giving early adopters a competitive edge. 

Note: Segment shares of all individual segments available upon report purchase

By Product: Membranes Surge as Chromatography Matures

Chromatography columns and resins commanded a 35.10% revenue share in 2025 and remain the reference standard for antibody capture. Yet filtration and membrane devices exhibit the highest 14.12% CAGR as PFAS-free polymer advances spur replacement cycles. The downstream processing market size for filtration products reached USD 12.2 billion in 2026 and is projected to hit USD 23.6 billion by 2031. Multi-layer depth filters reduce step count by combining clarification and fine filtration in one housing, enhancing facility productivity. 

Adaptive control valves and gamma-stable flow paths facilitate modular skid reconfiguration, appealing to CMOs juggling diverse client molecules. Chromatography suppliers respond with high-throughput resin screening kits that cut process development time by 30%. Single-use hardware adoption rises despite debates over disposal costs, as operators value the reduced validation burden. 

By Application: Antibody Production Leads, Cell Therapy Surges

Antibody programs maintained a 43.30% share of 2025 revenues, while cell and gene therapies expanded at a 14.90% CAGR, translating into an estimated downstream processing market size of USD 10.3 billion for CGT in 2026. Eight FDA approvals in 2024 validate commercial viability, powering investment in closed-system sterile filtration and viral-vector clarification technologies. 

Antibody-drug conjugate pipelines introduce hydrophobic payloads, complicating purification and boosting demand for mixed-mode resins. Vaccine manufacturers leverage mRNA-specific purification resins that tolerate higher alcohol concentrations without ligand leaching. Automation prototypes for autologous cell therapy harvest are entering GMP suites to reduce manual operations, which currently account for 35% of total batch labor cost. 

Note: Segment shares of all individual segments available upon report purchase

By End User: Biopharma Manufacturers Lead, CDMOs Accelerate

Biopharmaceutical manufacturers accounted for 48.10% of 2025 revenue, yet increasingly rely on CDMO partnerships for capacity and specialised modalities. CDMOs are projected to hold the majority of the downstream processing market share by 2028, with a 15.10% CAGR. Digital twin deployment at service providers standardises run-to-run performance, attracting small biotech clients short on in-house process development resources. 

Academic institutes are adopting single-use to shorten tech transfer to CDMOs. Government agencies maintain a niche demand for mRNA and viral vector capacity to support strategic stockpile goals. End users are converging on quality-by-design frameworks, pushing suppliers to embed multivariate analytics into skid controllers to streamline regulatory submissions. 

Geography Analysis

North America recorded a 32.50% revenue share in 2025, powered by large-scale investments such as Johnson & Johnson鈥檚 USD 2 billion project in North Carolina. Regional producers adopt continuous manufacturing on 75% of new lines and plan to integrate artificial intelligence within 3 years. The downstream processing market benefits from the FDA鈥檚 proactive stance on innovative manufacturing guidance, fostering investor confidence in novel purification platforms. 

Asia-Pacific is the fastest-growing region, with a 14.35% CAGR, due to large-scale facilities in South Korea, China, Singapore, and India. Samsung Biologics adds 180,000 L capacity while Novartis expands its Singapore site, exemplifying a trend toward mega-facilities supporting global supply. Indian CDMOs position themselves as alternatives following the United States Biosecurity Act. Regional authorities subsidise workforce training to bridge gaps in process-engineering talent and encourage local sourcing of filters and bags.